OneSkin Secures $20M Series A from Prelude Growth
Slice of Healthcare Team
08/14/2025
Key highlights
- $20M Series A funding led by Prelude Growth Partners.
- Investment supports science-driven skin longevity innovations.
- OneSkin replaces early investor with long-term growth partner.
- Proprietary peptide OS-01 targets skin aging at the cellular level.
Source: PR Newswire
Notable Quotes
“ Their team's expertise in building modern consumer brands and their enthusiasm for our science-driven approach made this a natural fit... We got ourselves a dream team! ”
Carolina Reis Oliveira, PhD, Co-Founder & CEO at OneSkin
“ OneSkin's cutting edge science, novel proprietary technology, leadership in skin longevity, and compelling brand are truly unique in the category." ”
Alicia Sontag, Co-Founder & Managing Partner at Prelude Growth Partners
Why This Matters
This investment solidifies skin longevity as a growing category in the beauty and wellness industry, signaling increased investor interest in biotech-backed personal care solutions. By partnering with Prelude Growth Partners, OneSkin gains the resources and expertise to expand its product line, enhance scientific research, and strengthen its position as a leader in anti-aging innovation. The funding also reflects a broader shift toward longevity science—addressing the root causes of aging rather than surface-level symptoms—setting the stage for a new era in skincare.
